In the field of drug development, the exploitation of chemical platforms for the identification of novel druggable molecules has become common place in many research laboratories. In recent years, the characterisation of novel bioactives, that often share chemical properties commonly found in many nature products, or molecules that are critical in cell signalling systems, has gained much attention. Synthetic routes of production, and allied platforms in the characterisation of druggable entities continues to drive advances in this field. The multidisciplinary nature of the research has led to the design and refinement of natural products-like drug candidates, and in the synthesis of biological mimetics they function as cellular antioxidants, as enzymes mimetics, or as novel molecules that have the capacity to release signalling molecules in tissues.
This Research Topic aims to exploit recent findings and innovative approaches in chemistry that are driving developments in the identification and exploitation of novel druggable candidate molecules. This field has been driven by multidisciplined approaches that are allowing for close collaboration between chemists, biochemists, pharmacologists, and biomedical scientists. The collective nature of this research is allowing for the rapid identification of novel chemical entities, the assessment of biological properties, and the further refinement of lead molecules that allow for the identification of better drug lead molecules. The collaborative nature of this field is driving the development of novel therapies targeting many chronic conditions in humans viz. cancer(s), diabetes, arthritic conditions, among others. Druggable entities include a spectrum of novel molecules that act on signal transduction pathways, gene expression systems, function as novel cytotoxic molecules, angiogenesis inhibitors, anti-inflammatory compounds, and as molecules that mimic molecules that are diminished in diseased tissues. A key goal driving much of this research is to improve efficacy, enhance delivery to tissues, to reduce the toxicity, and to develop efficient synthetic routes.
This Research Topic focuses on the design, development and assessment of novel bioactive molecules as druggable candidates. We welcome Original Research, Review, Mini Review and Perspective articles on themes including, but not limited to:
• Assessment of chemicals to identify novel drug candidate molecules
• Synthesis, and characterizations of novel biological mimetics
• Design and development of drug candidates for the delivery of mammalian signalling molecules like hydrogen sulfide and other sulfur species
• Incorporation of novel biologics into biomedical applications
• Synthesis, characterizations, and pharmacological assessment of multifunctional bioactive molecules
In the field of drug development, the exploitation of chemical platforms for the identification of novel druggable molecules has become common place in many research laboratories. In recent years, the characterisation of novel bioactives, that often share chemical properties commonly found in many nature products, or molecules that are critical in cell signalling systems, has gained much attention. Synthetic routes of production, and allied platforms in the characterisation of druggable entities continues to drive advances in this field. The multidisciplinary nature of the research has led to the design and refinement of natural products-like drug candidates, and in the synthesis of biological mimetics they function as cellular antioxidants, as enzymes mimetics, or as novel molecules that have the capacity to release signalling molecules in tissues.
This Research Topic aims to exploit recent findings and innovative approaches in chemistry that are driving developments in the identification and exploitation of novel druggable candidate molecules. This field has been driven by multidisciplined approaches that are allowing for close collaboration between chemists, biochemists, pharmacologists, and biomedical scientists. The collective nature of this research is allowing for the rapid identification of novel chemical entities, the assessment of biological properties, and the further refinement of lead molecules that allow for the identification of better drug lead molecules. The collaborative nature of this field is driving the development of novel therapies targeting many chronic conditions in humans viz. cancer(s), diabetes, arthritic conditions, among others. Druggable entities include a spectrum of novel molecules that act on signal transduction pathways, gene expression systems, function as novel cytotoxic molecules, angiogenesis inhibitors, anti-inflammatory compounds, and as molecules that mimic molecules that are diminished in diseased tissues. A key goal driving much of this research is to improve efficacy, enhance delivery to tissues, to reduce the toxicity, and to develop efficient synthetic routes.
This Research Topic focuses on the design, development and assessment of novel bioactive molecules as druggable candidates. We welcome Original Research, Review, Mini Review and Perspective articles on themes including, but not limited to:
• Assessment of chemicals to identify novel drug candidate molecules
• Synthesis, and characterizations of novel biological mimetics
• Design and development of drug candidates for the delivery of mammalian signalling molecules like hydrogen sulfide and other sulfur species
• Incorporation of novel biologics into biomedical applications
• Synthesis, characterizations, and pharmacological assessment of multifunctional bioactive molecules
